Zur Rose consolidates its position in Germany
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Zur Rose through its DocMorris subsidiary has acquired German rival Apo-rot, in a move that will further bolster its position in the country’s online pharmacy market.
You may also be interested in...
Bricks-And-Mortar Pharmacy In The Crosshairs As Zur Rose Aims To Become The Amazon Of European Healthcare
Swiss supply chain disruptor Zur Rose wants to break up the ancient monopoly of European bricks-and-mortar pharmacy and replace it with a tech-driven healthcare offering to rival that of retail giant Amazon, according to a member of the firm’s board, Olaf Heinrich.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.